WO2014150935A1 - Method and products for enhancing drug and dietary supplement bioavailability - Google Patents

Method and products for enhancing drug and dietary supplement bioavailability Download PDF

Info

Publication number
WO2014150935A1
WO2014150935A1 PCT/US2014/024592 US2014024592W WO2014150935A1 WO 2014150935 A1 WO2014150935 A1 WO 2014150935A1 US 2014024592 W US2014024592 W US 2014024592W WO 2014150935 A1 WO2014150935 A1 WO 2014150935A1
Authority
WO
WIPO (PCT)
Prior art keywords
dietary
family
drug
dietary supplement
supplement
Prior art date
Application number
PCT/US2014/024592
Other languages
French (fr)
Inventor
Daryl L. BARNETT
Original Assignee
Cba Pharma, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cba Pharma, Inc filed Critical Cba Pharma, Inc
Priority to JP2016501583A priority Critical patent/JP2016514142A/en
Priority to CN201480028482.XA priority patent/CN105357966A/en
Priority to KR1020157029730A priority patent/KR20150143504A/en
Priority to EP14767625.8A priority patent/EP2986122A4/en
Priority to MX2015013158A priority patent/MX2015013158A/en
Publication of WO2014150935A1 publication Critical patent/WO2014150935A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Bioavailability for dietary supplem ns is sml r, aud A generally defned as the proportion of the ad ⁇ aistered s bslanoe capable of bei g absorbed nd available for use or storage, to both pharmacology and nuuition sciences, bioavadasenty Is meassupsd by calculating the arcs uader tbe curve (AU €> o 3 ⁇ 4e drug or dietary sup lement nceotradon lime profile.
  • Wher Rs am! i f are the same r different shostc ained carbo ased llgaod deluding without limtation CI! ⁇ €(>:>£!3 ⁇ 4 or U; d 3 ⁇ 4 is C3 ⁇ 4 or ' C2H3; and !v. s O E or hydmgsre d where the chem al a uctore lias the "S" i3 ⁇ 4>m «ri;c coagulati n at the ( 1 " chlrai csrfeon !oeMkm,
  • Sf Drugs & dietary au pieoioots are adsorbed through, fbe liolog of the alkacrstary ca al at dif!breot rates.
  • the oxieol t ich cooeorrent admioiatrahoo. of a d-telraodri3 ⁇ 4o fomify me b r enhooees the & mi md rate of soeb sra tioo will .also vary accordingly.
  • Those drugs and dietary- su leme ts with mpM d approaches complete rates of adsorption ma show little or no im rovetoera i bloadsorptsoa ara!
  • T3 ⁇ 4e -tetiamki e family member ami the drag or dietary soppleme t caa-fee foramlated toge&er kites a sm$de formula, they oaa bo tbra ⁇ u!sied separately aad adodmoiered sdher sroiihrnjie oaly sofBc ody close together thai they are boft m.
  • drag or dietary ao leioeai will vary from p réelleit to padeot aod as a i oohosi of the priocipk drug.
  • -or dteimy supplement used o lhin a raege of from about 0.04:1 to shoot 170:1.
  • a rnt typical rnge woak! he imm. about 1:1 to 100: 1, more preferabl !ror .25:75 to 75:25.
  • the dosage l el £1 ⁇ 2 hhe d-tebarKlnoe family member will vary fern case to eae, based an the patieot ai3 ⁇ 4s
  • ⁇ cm exist h ⁇ the tree base forn r 3 ⁇ 4s a mono or di-acid sab. Because of the enhanced solubility of the salt form of p rmae3 ⁇ 4 tleal mgredlems, the sab forms ar used, m brmibadng h maeeiaie i c>m os3 ⁇ 4ons.
  • the ⁇ active baeredieai bras solebitizes more qoieb!y and ertters sh 'bloodstream fmi&x.
  • the free base form h not soluble is water. Ho ever, it has .recently been surprisingly fours!
  • tbe free base form lations of d ⁇ irmm family member are absobed, into- the bloodstream sabsbmilai!y asTa dl as Ibrmelabons of the- dl-aeid salt m m es ⁇ the famiy, Acc rdingl ., vee pro ose to use either die free base or tbe di-aaid salt of the d-;ao ndnoe tbnilhy member ie oar ibmnuatioos.
  • P01@J T3 ⁇ 4e preferred formalatiorss comprise & mem e of tbe d-ietrandtbve family combined with a preparationabte phMirscea& f carrier.
  • the p tnToaeeutioal carrie ears be a liquid, or a. solid composition
  • a liquid carrier will preferably comprise water, possibly with additional lagredieois sued as ,25%
  • the solid carrier or dlu nt ' used be pregekinked.
  • starch mforoerystatlme eelkbose or the like, !t raay also be !brraolaied with other ingre ents, such as colloidal silicone dioxide, sodium lauryl sulfate and mag sx siear ie.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Enhancing the bioavailability of a drug or dietary supplement by administering it concurrently with one or more memebers of the d-tetrandrine family.

Description

METHOD AND FOE ENHANCING PM!JG AND DIETARY
SUPPLE E ΒΙΟΑΥΑΙΙ,ΑΒΜ,ΠΎ
CROSS REFE E CE TO R!TATtd) APPLICATIONS1 ¾ resent a licaton claims the enefit of 0.$. Ffw oaal Patera Application Ha.
61/792 ,7i¾ emitted METHOD A D PRODUCTS FOR LAilANCiNO DEOG ANT) DIETARY
SlFPPUiMK T BiO AiLABIIJl Ύ, A lea o March 15, 20 the entire corneals of which are
Ineo xjmed. by ?d½rence.
HELD AMD BACKGROUND OF TB f IN E T!O
] The resen kve k>& reat s O die ra iKtesTisi?Hti o of drugs .¾d dietary si^p½rooot . kieludlog nutr&ceuiiesis. The eiJcedveaess of drop and dieary supplent ras s in ari a
Amnion of 'their hl «vaJ:aMiAy lbIlow¾g <ral ingestion or ana! adsorption. Cle anally, the tem o;.r¾sij ability is the Iracdos oC ami isle at which, ' admloi stored dose of ooc angod drug is adsorbed through the ikhi of the alimentary canal imo sysiem.s circukdoo. Bioavailability for dietary supplem ns is sml r, aud A generally defned as the proportion of the ad^aistered s bslanoe capable of bei g absorbed nd available for use or storage, to both pharmacology and nuuition sciences, bioavadabildy Is meassupsd by calculating the arcs uader tbe curve (AU€> o ¾e drug or dietary sup lement nceotradon lime profile.
SUMMARY OF 11IE INVENTION
] It* the present..rtv tfk>* kloa^ i lability of dugs and dkiary supplements is enhanced b t e-coacuffcnl administration of artc a embers of ie d-iet nddne family of dr gs. The d- tetraodrme feroily members have the following structural formula:
Figure imgf000003_0001
Wher Rs am! if are the same r different shostc ained carbo ased llgaod deluding without limtation CI!^€(>:>£!¾ or U; d ¾ is C¾ or 'C2H3; and !v. s O E or hydmgsre d where the chem al a uctore lias the "S" i¾>m«ri;c coagulati n at the ( 1 " chlrai csrfeon !oeMkm,
DESCRIPTION OF THE PREFERRED EMBODIMENT
]
Figure imgf000003_0002
of thfc drtetrandrke iamtiy ncl de foe .followin re resentative exam l s, hich ars not foteoded to be exha stve:: d-ietraooinee, s tetraoddpe, hemande ine, berb&mioe, cis&mne. phaeanfoine, ob¾¾e me, $ ·.. fangcMsoHne m4 ikngchi o e. h ¾H of these exam le^ R ¾ and ¾s e HSiiete the i»etlhyt group. Variation iijk the. grotip occurs i»- ihm Ri and j m y constiute either a methyl grou or hydroe.ee. and fee is meric eooilguratfoe of " ix>mpmmd feeC-t md C-VMm rbm pmii either R reete) orS ($m m The r les for R aed S
Figure imgf000003_0003
be f um! . Morrlsoo m Boyd, '· "Or anic Chemistry,'' Edition, ee yrigj-p 1983 by Allya d Baccm, at pp. 38-14 L As ooied above, the ehir&j ooi¾tlg¾raiioi? at C-l ' is "S" .fo m mbers of the d-ista dnne family, lit addition, e saodezfoe irjejed s a taethoxy group ¾i the C-5 ostion. ¾ The most preferred ns-enbes of the claimed tetraadtiae amil t$ d-tetraodriae. Methods for extracting aaaVor ptaiyiog d-¾l.raidnae are disclosed in IIS, Patent 6.21B.;.54! d m !hjhKahod. Patet Application No.2011/0.105755,
Sf Drugs & dietary au pieoioots are adsorbed through, fbe liolog of the alkacrstary ca al at dif!breot rates. The oxieol t ich cooeorrent admioiatrahoo. of a d-telraodri¾o fomify me b r enhooees the & mi md rate of soeb sra tioo will .also vary accordingly. Those drugs and dietary- su leme ts with mpM d mots complete rates of adsorption ma show little or no im rovetoera i bloadsorptsoa ara! bioavaMabllty through the coticurmot oae of a. d-ieCfaodrme family membe, However, my drags nd dietary sisppleroeots with sk er and less complete rates of hloadyorpton. gad Moavadafhliiy wsli show impoved oavadabi!ity with, soch coitcormit use,
T] T¾e -tetiamki e family member ami the drag or dietary soppleme t caa-fee foramlated toge&er kites a sm$de formula, they oaa bo tbra^u!sied separately aad adodmoiered sdher sroiihrnjie oaly sofBc ody close together thai they are boft m. the aHmsssiiary esaa at: the same time, or they cao bo dminsered such dial the d-tada dr e femly rae.r«te is avadabtc hi the I rag of the ahmeraary canal a:t the time the drug or dietary su plement is ingested. The- d~ m¾di¾i &rasly ruembor: araj the drug or dietary so plemerd cm he Immol ed separately bul be sold as part of a "kt" The osage mi& of the d-tetraiddne family member to a. drag or dietary ao leioeai will vary from patieiit to padeot aod as a i oohosi of the priocipk drug. -or dteimy supplement used, o lhin a raege of from about 0.04:1 to shoot 170:1. A rnt typical rnge woak! he imm. about 1:1 to 100: 1, more preferabl !ror .25:75 to 75:25.
] It is believed tha the ptician dosage pro edure would, be to adidaisier the d- ramMne. idroily iner ber lo oral doses of from, ohoui 50 to about 10QQ oig ^r $ meter par day, more prei¾rabiy 250-700, and nmi preferably $hoW 500, (probably m two to four doses per d y), while admlm;aen¾g drug or detary supphimeni ^ufUaieous!y or en die same day. The dosage l el £½ hhe d-tebarKlnoe family member will vary fern case to eae, based an the patieot ai¾s| on the drug or dietary su lemen used. The dmg or dietary soppiemeui la adodnlstered. at sual dosage levels (possibly somewhat less m view of the effect of the d- tetramlrioe iiies er ou bioayab&bihby) on.ee' 'w more during the coarse of die ddetmndrme fern by mem er dosiag,
PSO 9J The d-te¾am «e family bishen^yhso brublues have w mtrogen locatioos and bence
■cm exist h\ the tree base forn r ¾s a mono or di-acid sab. Because of the enhanced solubility of the salt form of p rmae¾ tleal mgredlems, the sab forms ar used, m brmibadng h maeeiaie i c>m os¾ons. The■active baeredieai bras solebitizes more qoieb!y and ertters sh 'bloodstream fmi&x. The free base form h not soluble is water. Ho ever, it has .recently been surprisingly fours! by a co-worker that tbe free base form lations of d^irmm family member are absobed, into- the bloodstream sabsbmilai!y asTa dl as Ibrmelabons of the- dl-aeid salt m m es ο the famiy, Acc rdingl ., vee pro ose to use either die free base or tbe di-aaid salt of the d-;ao ndnoe tbnilhy member ie oar ibmnuatioos.
P01@J T¾e preferred formalatiorss comprise & mem e of tbe d-ietrandtbve family combined with a soitabte phMirscea& f carrier. The p tnToaeeutioal carrie ears, be a liquid, or a. solid composition, A liquid carrier will preferably comprise water, possibly with additional lagredieois sued as ,25%
Figure imgf000005_0001
The solid carrier or dlu nt 'used be pregekinked. starch, mforoerystatlme eelkbose or the like, !t raay also be !brraolaied with other ingre ents,, such as colloidal silicone dioxide, sodium lauryl sulfate and mag sx siear ie. |0ϋ11| A 2CK) mg e&p e, table? - \$ψύύ dosage forroi sdor? s m st preferred. The most preferred dose of. about 500 mg/¾ &ro meier/day ½ rou hl 1C¾$) ffig per day for a 190 pouad atient: six- feci tall Soeh a patient can j .fill the dosage re idr moirds by taking five e& syks deriog the coarse of the day, f exam le three In fbs moB&n md two m tie evEdog, or d«e at a me spae d os¾ over die day; A. smaller erson wc¾: k¾ 125 pounds a a height of fi e eet six Inch s woold require few 200.mg eapeuks d ris the eoiirse of the d&y.
f S12J Of course, is- understood that fho fojigohig j¾¾ preferr emhodiffieBts of the kveniioa* an that i cms .e&a be employe without de artn £ the spirit of Iks invention as s t fords In the. p oded claims, interpreted s aec rd^ce with the pri m les of gsterii: la .

Claims

j.. A .meth d iT h rscing ie bksavasMbillly of ru s and dietary su Lmc cumprs:>inu: the co rmi admi&btraiion of a drug or dietary 'Su ement and a jticmber of ih d eimm!rine famly e>f d:rag$ feei the i¾I w¾g'^ru i«rl Ι«¾ιΛ:
Figure imgf000007_0001
ore Γ! and Rt' at¾ the same or drffeest short chained earl». hasod. hg sid mekidmg w hout Umuad n. CHy.€Oa€¾ or 11; and ;; CM; or and Hi C¾ or d gen, ax$d hetem sad stoet«f¾ formula das e " " is m ric 0 i u»¾tkm at the€~ I f dh½l cab toealioii:,
2. The method afeiaim I &erefe said m mber of the d- randnsie family is selected from ώ« group eorsxbiin of: ddctimdr , isoeraisdtfee, hemaBd.ezi»e, bcrbamde, pycraainnje, ha^mlfdne, <h<¾me i»e,. eth l taa diio lme md & ^ bmi ^
3. The meth d of claim 1 wte¾i« said member of the skei andxfto family x& d-tetrandrifl
4. The method of claim 3 m which the d- ra drivie- T nly member is ¾se<i in ¾¾«> .a with ¾ dkiary su lemnt . The. RISIJKKI of claim 4 n which t e d^etrs rme family Briber and the dietary supplement arc ftmrridated t ether into a s gU i n i ,
6. The t d of clai 3 in which the d^ haadrme family em er is sed in e^junctibe wii a g,
7. The meh d of claim 6 which ike ddemaoH e family member md the drug are ormulate together a single form la
K. The method of claim 1 in wbicfe the e£ratidrifte family member is used in coopsa oo will? a drug,,
9. Ί'¼ method of claim I m which the d^oir&nb½e family member is used in c r¾uncfloo with dietary supp emeox
HI The method of claim I i 'which the drug or dietary supplement oormaHy has a rate of bioavakhOiiy which is die slower u<ior less complete one third poriioo af a scale of bioavailability for various drop and dietary a pp jsem. 11, The method of claim t m which she doetraadr e famil member and the drug or dietary sup lement are formulated together ioto a siogle tboiiuJa.
12, The Htediod of cl im 1. » w cb the d~tetr&adnoe hmiiy m m er md the drag- or dietary supplement are form lated 'se araely and adMiossiered either ss !iaae sl or sufficiently close together tliat die 5dR8A is exposed to bold s¾«uHaaco sl ,
13, The meth d- of ekdni I ia w ch the d-iEinmdrme family mber and dru or dietary sappiemeoi are ad rami si rf m a usage radii f d-tetmadrsoe famly msate to dreg or
Figure imgf000009_0001
1 The oiethod of clai ! m wbieh the dooimodrbic -family meoda-r sod drug r dietary sap leosesjt ase admins see red m a usage ratio of d etrandriue family member to- drug tar dietary supplement, within a taagc of from shout 1 to 100,
15- The .m th d -of cislai 1 m whi h the d-terasdrme tatni!y member a d drug or dtemy sappiemeot are adroioisterei a usage ati of d otmndrme family member to drag or dietary su lemesi, wiih a range of fk>m. a om 25:75 to 75:25,
Id. The me o of ekiat I hi which the d-tetra»driae family is admmsstered in oral doses of from, about 50 to about tOOff i»g per -s uare scoter per day -over a : -period of from about 4 to about 1 days, and the drug or dietar supplement Is then adnnsnstered . usual dosage levels onoe ormer during said 4 to 1 . clays.
17. The met od of claim 1 hich the d-tetmadxlnsi l¾mily is &dmi«iste«4 i« «?«! doses of from about 250-7 1 mg per square eer per day over said period of from about 4 to a ut 14 d y¾>. lit Th&- saeibod. of caim- II in which ihc. d- aadrine. famil admir siered m om! d ses of aoal 500 aig r scus¾« mzt&r p day o er said p riod of frsm ab iii 4 to ahom 14 days, in. ivaa I.Q four doses per day ,
1 , A diet y sup lement composition e«.» isbg a dea ^pleraettt c mbined with a taeio er of he d-tete«di¾: family having the IbHowhg. sir ctuml feorrdtt:
Figure imgf000010_0001
where R:; and Rs! are tbe same or di0½¾«i short chained vstihm teed gsmd. dud g thout limtation, Ci¾ CXfeCI-b or R; md ¾ ¾ CRs or C¾Ey aod 3 ¼ Clh m yd gm, md herem d stru tal. f mmls has e 4¾ somerc configuration at the€ * άύ earfooBloeatio 2ϋ. A k n met dmg a dfeisy su plement, id a fonnuktkni com rising a ember of the d- ie?ri¾ i¾e mly havin the following structural formula:
Figure imgf000011_0001
w ere R; <& Ry ¾se the same or diifcrom: sh rt ehaaed C&≠ M based Bg¾ad ncludin without lism ion. C -: Ci¾CB-.j or H; and R2 Is€¾ or€¾H*.; and ¾ b C¾ o fey rogej. ad wherem said sl icural formula ' the isom ric e«-» s.¾raiioa a the C-i ? third carta kicmkm.
PCT/US2014/024592 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability WO2014150935A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2016501583A JP2016514142A (en) 2013-03-15 2014-03-12 Methods and products for enhancing the bioavailability of drugs and nutritional supplements
CN201480028482.XA CN105357966A (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability
KR1020157029730A KR20150143504A (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability
EP14767625.8A EP2986122A4 (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability
MX2015013158A MX2015013158A (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792700P 2013-03-15 2013-03-15
US61/792,700 2013-03-15

Publications (1)

Publication Number Publication Date
WO2014150935A1 true WO2014150935A1 (en) 2014-09-25

Family

ID=51529972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024592 WO2014150935A1 (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability

Country Status (7)

Country Link
US (1) US9345257B2 (en)
EP (1) EP2986122A4 (en)
JP (1) JP2016514142A (en)
KR (1) KR20150143504A (en)
CN (1) CN105357966A (en)
MX (1) MX2015013158A (en)
WO (1) WO2014150935A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3038655A4 (en) * 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing cellular uptake of drug and dietary supplements
EP2986122A4 (en) 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing drug and dietary supplement bioavailability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US20070027181A1 (en) * 2004-08-03 2007-02-01 Education Center Of Traditional Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086915A (en) 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
EP3038655A4 (en) * 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing cellular uptake of drug and dietary supplements
EP2986122A4 (en) 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing drug and dietary supplement bioavailability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US20070027181A1 (en) * 2004-08-03 2007-02-01 Education Center Of Traditional Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JIA WEI, SYNERGISTIC INTERACTION BETWEEN TETRANDRINE AND CHEMOTHERAPEUTIC AGENTS AND INFLUENCE OF TETRANDRINE ON CHEMOTHERAPEUTIC AGENT-ASSOCIATED GENES IN HUMAN GASTRIC CANCER CELL LINES
LIEBERMAN, SYNERGY BETWEEN TETRANDRINE AND FK506 IN PREVENTION OF DIABETES IN BB RATS
See also references of EP2986122A4 *
SHI JIAN-PING, SYNERGISTIC EFFECTS OF TETRANDRINE ON THE ANTIFUNGAL ACTIVITY OF TOPICAL KETOCONAZOLE CREAM IN THE TREATMENT OF DERMATOPHYTOSES
YOUNG-SEOB LEE, SYNERGISTIC EFFECT OF TETRANDRINE AND ETHIDIUM BROMIDE AGAINST MRSA

Also Published As

Publication number Publication date
EP2986122A4 (en) 2017-01-18
JP2016514142A (en) 2016-05-19
KR20150143504A (en) 2015-12-23
US20140275140A1 (en) 2014-09-18
EP2986122A1 (en) 2016-02-24
MX2015013158A (en) 2016-04-15
US9345257B2 (en) 2016-05-24
CN105357966A (en) 2016-02-24

Similar Documents

Publication Publication Date Title
HRP20180904T1 (en) Pharmaceutical dosage form comprising 6&#39;-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4&#39;,9&#39;-dihydro-3&#39;h-spiro[cyclohexane-1,1&#39;-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
ES2638517T3 (en) Arylmethoxy isoindoline derivatives and compositions comprising them and methods of use thereof
HRP20151337T1 (en) Pharmaceutical dosage form comprising 6&#39;-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4&#39;,9&#39;-dihydro-3&#39;h-spiro[cylohexane-1,1&#39;-pyrano[3,4,b]indol]-4-amine
JP2013505205A5 (en)
WO2007108990A3 (en) Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
FI3313408T3 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
JP2010513229A5 (en)
TN2012000362A1 (en) Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
MX2009007784A (en) Compositions of stable tiacumicins.
EP2986122A1 (en) Method and products for enhancing drug and dietary supplement bioavailability
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
RU2008134874A (en) METHOD FOR INCREASING DRY MUSCULAR MASS AND REDUCING FAT TISSUE
JP2012533565A5 (en)
NZ630494A (en) Administration of lorcaserin to individuals with renal impairment
HRP20210418T1 (en) Syd985 treatment of t-dm1 refractory cancer patients
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
RU2008129615A (en) COMBINATION OF 5-HT4 AGONIST AND CHOLINESTERASE INHIBITOR
WO2012064159A3 (en) Anticancer composition
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
JP2007508298A5 (en)
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same
MX2007015171A (en) Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
RU2012136190A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT
RU2013109134A (en) DOSAGE FORM THAT CONTAINS 6&#39;-FLUOR- (N-METHYL-OR N, N-DIMETHYL -) - 4-PHENYL-4 &#39;, 9&#39;-DIHYDRO-3&#39;N-SPIRO [CYCLOGEXAN-1,1&#39;- PIRANO [3,4, b] INDOL] -4-AMIN

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480028482.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14767625

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016501583

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/013158

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2014767625

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157029730

Country of ref document: KR

Kind code of ref document: A